Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells

Cancer Letters

Volumn 273, Issue 2, 2009, Pages 250-256

  Nakagawa, Takayuki ^a   Shimizu, Masahito ^a   Shirakami, Yohei ^a   Tatebe, Hideharu ^a   Yasuda, Ichiro ^a   Tsurumi, Hisashi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acyclic retinoid; Apoptosis; Gemcitabine; Pancreatic cancer; Synergism

Indexed keywords

ALITRETINOIN; GEMCITABINE; RAS PROTEIN; RETINOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN P21(RAS); PANCREATIC NEOPLASMS; RETINOIDS;

EID: 57349177603     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.004     Document Type: Article

References (37)

1. Chua Y.J., and Zalcberg J.R. Pancreatic cancer-is the wall crumbling?. Ann. Oncol. (2008)
2. Pierantoni C., Pagliacci A., Scartozzi M., Berardi R., Bianconi M., and Cascinu S. Pancreatic cancer: progress in cancer therapy. Crit. Rev. Oncol. Hematol. 67 (2008) 27-38
3. Burris 3rd H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 (1997) 2403-2413
4. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25 (2007) 1960-1966
5. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10 (1996) 940-954
6. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
7. Rosewicz S., Stier U., Brembeck F., Kaiser A., Papadimitriou C.A., Berdel W.E., et al. Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology 109 (1995) 1646-1660
8. Bold R.J., Ishizuka J., Townsend Jr. C.M., and Thompson J.C. All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. Pancreas 12 (1996) 189-195
9. Balasubramanian S., Chandraratna R.A., and Eckert R.L. Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. Carcinogenesis 25 (2004) 1377-1385
10. Pettersson F., Colston K.W., and Dalgleish A.G. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 23 (2001) 273-279
11. Michael A., Hill M., Maraveyas A., Dalgleish A., and Lofts F. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer-report of a pilot phase II study. Clin. Oncol. (R. Coll. Radiol.) 19 (2007) 150-153
12. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334 (1996) 1561-1567
13. Muto Y., Moriwaki H., and Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med. 340 (1999) 1046-1047
14. Suzui M., Masuda M., Lim J.T., Albanese C., Pestell R.G., and Weinstein I.B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res. 62 (2002) 3997-4006
15. Suzui M., Sunagawa N., Chiba I., Moriwaki H., and Yoshimi N. Acyclic retinoid, a novel synthetic retinoid, induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle- and differentiation-related molecules in human colon carcinoma cells. Int. J. Oncol. 28 (2006) 1193-1199
16. Shimizu M., Suzui M., Deguchi A., Lim J.T., and Weinstein I.B. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin. Cancer Res. 10 (2004) 1130-1140
17. Obora A., Shiratori Y., Okuno M., Adachi S., Takano Y., Matsushima-Nishiwaki R., et al. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 36 (2002) 1115-1124
18. Shimizu M., Suzui M., Deguchi A., Lim J.T., Xiao D., Hayes J.H., et al. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin. Cancer Res. 10 (2004) 6710-6721
19. Kanamori T., Shimizu M., Okuno M., Matsushima-Nishiwaki R., Tsurumi H., Kojima S., et al. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci. 98 (2007) 431-437
20. Tatebe H., Shimizu M., Shirakami Y., Tsurumi H., and Moriwaki H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin. Cancer Res. 14 (2008) 2806-2812
21. Shimizu M., Hara A., Okuno M., Matsuno H., Okada K., Ueshima S., et al. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology 33 (2001) 569-576
22. Bold R.J., Chandra J., and McConkey D.J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann. Surg. Oncol. 6 (1999) 279-285
23. Noble S., and Goa K.L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54 (1997) 447-472
24. Araki H., Shidoji Y., Yamada Y., Moriwaki H., and Muto Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem. Biophys. Res. Commun. 209 (1995) 66-72
25. Vickers S.M., Sampson L.K., Ying W., and Phillips J.O. Receptor-dependent growth inhibition of human pancreatic cancer by 9-cis retinoic acid. J. Gastrointest. Surg. 1 (1997) 174-181 discussion 81
26. Albrechtsson E., Ohlsson B., and Axelson J. The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. Pancreas 25 (2002) 49-56
27. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., and Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53 (1988) 549-554
28. Sakorafas G.H., Tsiotou A.G., and Tsiotos G.G. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat. Rev. 26 (2000) 29-52
29. Koorstra J.B., Hustinx S.R., Offerhaus G.J., and Maitra A. Pancreatic carcinogenesis. Pancreatology 8 (2008) 110-125
30. Matsushima-Nishiwaki R., Okuno M., Adachi S., Sano T., Akita K., Moriwaki H., et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 61 (2001) 7675-7682
31. Haklai R., Elad-Sfadia G., Egozi Y., and Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother. Pharmacol. 61 (2008) 89-96
32. Réjiba S., Wack S., Aprahamian M., and Hajri A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 98 (2007) 1128-1136
33. Shao R.X., Otsuka M., Kato N., Taniguchi H., Hoshida Y., Moriyama M., et al. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 128 (2005) 86-95
34. Holzmann K., Kohlhammer H., Schwaenen C., Wessendorf S., Kestler H.A., Schwoerer A., et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res. 64 (2004) 4428-4433
35. Ng S.S.W., Tsao M.S., Chow S., and Hedley D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60 (2000) 5451-5455
36. Bondar V.M., Sweeney-Gotsch B., Andreeff M., Mills G.B., and McConkey D.J. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 1 (2002) 989-997
37. Tooker P., Yen W.C., Ng S.C., Negro-Vilar A., and Hermann T.W. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 67 (2007) 4425-4433